Entrada Therapeutics (TRDA) to Release Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Entrada Therapeutics to post earnings of ($1.06) per share and revenue of $7.41 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

Entrada Therapeutics Stock Up 0.2%

NASDAQ:TRDA opened at $11.04 on Thursday. Entrada Therapeutics has a 12-month low of $4.93 and a 12-month high of $13.82. The firm has a market capitalization of $421.95 million, a price-to-earnings ratio of -4.43 and a beta of -0.12. The stock’s 50 day moving average price is $10.81 and its two-hundred day moving average price is $8.17.

Wall Street Analyst Weigh In

TRDA has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday. Oppenheimer initiated coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a report on Monday, December 29th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Finally, Roth Mkm set a $13.00 price objective on shares of Entrada Therapeutics in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.50.

Insider Activity

In other news, CFO Kory James Wentworth sold 8,910 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $9.98, for a total transaction of $88,921.80. Following the transaction, the chief financial officer directly owned 110,026 shares of the company’s stock, valued at approximately $1,098,059.48. This trade represents a 7.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.11% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd raised its holdings in Entrada Therapeutics by 26.4% in the 4th quarter. XTX Topco Ltd now owns 117,668 shares of the company’s stock valued at $1,210,000 after acquiring an additional 24,589 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the period. Sphera Funds Management LTD. bought a new position in shares of Entrada Therapeutics in the fourth quarter worth $1,140,000. Quadrature Capital Ltd raised its stake in Entrada Therapeutics by 13.5% in the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock valued at $209,000 after purchasing an additional 2,424 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in Entrada Therapeutics during the fourth quarter worth about $144,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.